Anti-HER2/ErbB2 Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - P04626

Core Product Specifications and Parameters

Biological Background: HER2/ErbB2 Function and Localization

• HER2/ErbB2 (receptor tyrosine-protein kinase erbB-2, also known as Neu, CD340, p185erbB2) is a member of the epidermal growth factor receptor (EGFR/ERBB) family, encoded by the ERBB2 proto-oncogene. It functions as an oncogenic driver in various cancers.
• The protein acts as an essential coreceptor within neuregulin-receptor complexes, lacking direct ligand-binding capacity but mediating signal transduction upon heterodimerization with other ERBB members. Activation triggers downstream pathways, including the MEMO1-RHOA-DIAPH1 signaling cascade, which inhibits GSK3B, leading to microtubule capture and stabilization at the cell periphery.
• In the nucleus, HER2/ErbB2 serves as a transcriptional regulator. It binds the PTGS2/COX-2 promoter at the 5'-TCAAATTC-3' sequence to activate transcription and is implicated in CDKN1A transcriptional activation via STAT3 and SRC. Additionally, it enhances rRNA transcription by RNA polymerase I, promoting protein synthesis and cell growth.
• Subcellularly, HER2/ErbB2 localizes primarily to the cell membrane, including ruffle membranes, and traffics through early endosomes. It is also found in the cytoplasm, perinuclear region, and nucleus, reflecting its dynamic signaling and regulatory roles.
• Post-translational modifications include glycosylation, phosphorylation, and disulfide bond formation, consistent with its receptor tyrosine kinase nature. The protein possesses ATP-binding and kinase domains critical for enzymatic activity.
• HER2/ErbB2 is overexpressed in a wide range of tumor tissues, particularly breast, small bowel, esophageal, kidney, and oral tumors. Its tissue-specific overexpression makes it a key clinical biomarker and therapeutic target.
• The UniProt record annotates HER2/ErbB2 with features like alternative initiation, alternative splicing, chromosomal rearrangement, and disease variants, underscoring its significance in cancer biology.

Experimental Guidance and Technical Tips

• The polyclonal antibody was raised against a synthetic peptide encompassing amino acids 1156–1255, corresponding to the C-terminal intracellular domain of human HER2/ErbB2. This region is conserved across human, mouse, and rat, supporting the observed cross-reactivity.
• For Western blotting, a band near 138 kDa is expected. Use positive control lysates from HER2-overexpressing cell lines (e.g., SK-BR-3, BT-474) and validate with appropriate negative controls.
• In immunohistochemistry (paraffin), consider antigen retrieval methods and validation using known HER2-positive breast carcinoma sections. Signal may be membranous, cytoplasmic, or both, depending on fixation and tumor characteristics.
• For ELISA, the antibody may be used as capture or detection reagent against recombinant HER2/ErbB2 protein or peptide; pairing with a well-characterized monoclonal antibody might enhance assay performance.
• Optimization of dilution factors and incubation conditions is recommended across all applications.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines IVD raw-material procurement for diagnostic manufacturers and research teams by offering a comprehensive portfolio of antibodies, antigens, and ancillary reagents. This anti-HER2/ErbB2 rabbit polyclonal antibody is part of our oncology-focused collection, which also includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk reagents for large-scale assay development. Whether you require rare-target sourcing, custom immunogen design, or full technical consultation, CamelBio serves as your reliable single-vendor bridge from concept to clinic.